tradingkey.logo

Journey Medical Corp

DERM
8.350USD
0.0000.00%
終値 02/06, 16:00ET15分遅れの株価
220.21M時価総額
損失額直近12ヶ月PER

Journey Medical Corp

8.350
0.0000.00%

詳細情報 Journey Medical Corp 企業名

Journey Medical Corporation is a commercial-stage pharmaceutical company. The Company is focused on selling and marketing of the United States Food and Drug Administration (FDA) approved prescription pharmaceutical products for the treatment of dermatological conditions. Its portfolio includes eight FDA-approved prescription drugs for dermatological conditions that are marketed in the United States. Its marketed products, which have been approved FDA for sale in the United States, include Qbrexza, Accutane, Amzeeq, Zilxi, Exelderm Cream and Solution, Targadox, and Luxamend. Qbrexza is a medicated cloth towelette for the treatment of primary axillary hyperhidrosis. Accutane is an oral isotretinoin drug for the treatment of severe recalcitrant nodular acne. Targadox is an oral doxycycline drug for adjunctive therapy for severe acne. Luxamend is a water-based emulsion formulated to provide moist healing environment.

Journey Medical Corpの企業情報

企業コードDERM
会社名Journey Medical Corp
上場日Nov 12, 2021
最高経営責任者「CEO」Maraoui (Claude)
従業員数41
証券種類Ordinary Share
決算期末Nov 12
本社所在地9237 E Via De Ventura Blvd., Suite 105
都市SCOTTSDALE
証券取引所NASDAQ OMX - NASDAQ BASIC
United States of America
郵便番号85258
電話番号14804346670
ウェブサイトhttps://journeymedicalcorp.com/
企業コードDERM
上場日Nov 12, 2021
最高経営責任者「CEO」Maraoui (Claude)

Journey Medical Corpの経営陣

会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+1239123.00%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+50000.00%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+46863.00%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+28907.00%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+20000.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+20000.00%
Mr. Michael C. Pearce
Mr. Michael C. Pearce
Independent Director
Independent Director
57.17K
+20000.00%
Mr. Justin Smith
Mr. Justin Smith
Independent Director
Independent Director
--
--
Ms. Jaclyn Jaffe
Ms. Jaclyn Jaffe
Investor Relations
Investor Relations
--
--
会社名
会社名/ポジション
ポジション
株式保有
変動額
Mr. Claude Maraoui
Mr. Claude Maraoui
President, Chief Executive Officer, Director
President, Chief Executive Officer, Director
2.06M
+1239123.00%
Dr. Lindsay A. Rosenwald, M.D.
Dr. Lindsay A. Rosenwald, M.D.
Executive Chairman of the Board
Executive Chairman of the Board
377.89K
+50000.00%
Mr. Ramsey Alloush
Mr. Ramsey Alloush
Chief Operating Officer, General Counsel
Chief Operating Officer, General Counsel
316.68K
+46863.00%
Mr. Joseph Benesch, CPA
Mr. Joseph Benesch, CPA
Chief Financial Officer, Corporate Controller
Chief Financial Officer, Corporate Controller
100.78K
+28907.00%
Mr. Neil Herskowitz
Mr. Neil Herskowitz
Independent Director
Independent Director
98.89K
+20000.00%
Ms. Miranda Jayne Toledano
Ms. Miranda Jayne Toledano
Independent Director
Independent Director
98.89K
+20000.00%

収益内訳

通貨: USD更新時刻: Tue, Jan 6
通貨: USD更新時刻: Tue, Jan 6
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
事業別USD
会社名
収益
比率
Qbrexa
7.36M
43.23%
Emrosi
4.88M
28.68%
Accutane
2.77M
16.26%
Amzeeq
1.31M
7.71%
Other branded revenue
702.00K
4.12%
地域別USD
会社名
収益
比率
United States
17.63M
0.00%
事業別
地域別
事業別USD
会社名
収益
比率
Qbrexa
7.36M
43.23%
Emrosi
4.88M
28.68%
Accutane
2.77M
16.26%
Amzeeq
1.31M
7.71%
Other branded revenue
702.00K
4.12%

株主

更新時刻: Sat, Jan 31
更新時刻: Sat, Jan 31
株主統計
種類
株主統計
株主統計
比率
Fortress Biotech Inc
12.33%
Maraoui (Claude)
7.56%
Tang Capital Management, LLC
6.80%
Wasatch Global Investors Inc
4.79%
Opaleye Management Inc.
3.56%
他の
64.95%
株主統計
株主統計
比率
Fortress Biotech Inc
12.33%
Maraoui (Claude)
7.56%
Tang Capital Management, LLC
6.80%
Wasatch Global Investors Inc
4.79%
Opaleye Management Inc.
3.56%
他の
64.95%
種類
株主統計
比率
Corporation
12.33%
Individual Investor
12.01%
Hedge Fund
11.42%
Investment Advisor
10.16%
Investment Advisor/Hedge Fund
9.10%
Private Equity
0.84%
Insurance Company
0.66%
Research Firm
0.31%
Pension Fund
0.15%
他の
43.02%

機関投資家保有株

更新時刻: Mon, Dec 8
更新時刻: Mon, Dec 8
報告期間
機関投資家数
保有株式数
比率
変動額
2025Q4
111
6.92M
29.29%
--
2025Q3
113
6.92M
33.12%
+300.88K
2025Q2
111
6.62M
36.44%
+1.49M
2025Q1
80
5.12M
29.92%
+3.29K
2024Q4
74
3.80M
30.46%
+100.75K
2024Q3
75
2.18M
26.36%
-187.63K
2024Q2
70
2.37M
22.85%
+547.02K
2024Q1
61
1.83M
18.72%
-778.53K
2023Q4
59
1.36M
20.20%
-795.63K
2023Q3
44
2.15M
17.23%
+484.38K
詳細を見る

株主動向

会社名
保有株式数
比率
変動額
変動率
日付
Fortress Biotech Inc
3.36M
15.9%
--
--
Apr 14, 2025
Maraoui (Claude)
2.06M
9.75%
+1.24M
+150.79%
Aug 25, 2025
Tang Capital Management, LLC
1.85M
8.77%
--
--
Sep 30, 2025
Wasatch Global Investors Inc
1.31M
6.18%
+154.21K
+13.39%
Sep 30, 2025
Opaleye Management Inc.
971.06K
4.59%
+876.06K
+922.17%
Sep 30, 2025
The Vanguard Group, Inc.
615.23K
2.91%
+50.24K
+8.89%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
571.92K
2.71%
+91.62K
+19.08%
Sep 30, 2025
Summit Financial, LLC
379.83K
1.8%
+379.83K
--
Sep 30, 2025
Rosenwald (Lindsay A)
377.89K
1.79%
+50.00K
+15.25%
Aug 05, 2025
Essex Investment Management Company, LLC
354.02K
1.68%
+125.82K
+55.13%
Sep 30, 2025
詳細を見る

関連ETF

更新時刻: Sat, Dec 6
更新時刻: Sat, Dec 6
銘柄名
比率
iShares Micro-Cap ETF
0.02%
iShares Russell 2000 Growth ETF
0.01%
Global X Russell 2000 ETF
0%
ProShares Hedge Replication ETF
0%
iShares Russell 2000 ETF
0%
DFA Dimensional US Sustainability Core 1 ETF
0%
Dimensional US Core Equity 1 ETF
0%
ProShares UltraPro Russell2000
0%
Royce Quant Small-Cap Quality Value ETF
0%
Proshares Ultra Russell 2000
0%
iShares Micro-Cap ETF
比率0.02%
iShares Russell 2000 Growth ETF
比率0.01%
Global X Russell 2000 ETF
比率0%
ProShares Hedge Replication ETF
比率0%
iShares Russell 2000 ETF
比率0%
DFA Dimensional US Sustainability Core 1 ETF
比率0%
Dimensional US Core Equity 1 ETF
比率0%
ProShares UltraPro Russell2000
比率0%
Royce Quant Small-Cap Quality Value ETF
比率0%
Proshares Ultra Russell 2000
比率0%

配当金

過去5年間の配当金総支払額は 0.00 米ドルである。
日付
配当金
権利確定日
支払日
配当落ち日
データなし

株式分割

日付
配当落ち日
種類
比率
データなし
日付
配当落ち日
種類
比率
データなし
KeyAI